DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Real-time Bid/Ask 13:30:56 16/07/2024 BST | ||
| 1.31 EUR / 1.45 EUR | +8.66% |
|
| Current month | -2.31% | ||
| 1 month | -2.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 16/07/24 | 1.3 | +2.36% |
| 15/07/24 | 1.27 | -1.55% |
| 12/07/24 | 1.29 | -5.15% |
| 11/07/24 | 1.36 | +0.74% |
| 10/07/24 | 1.35 | 0.00% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 10:45 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7Y |
| ISIN | DE000MG0D7Y8 |
| Date issued | 18/03/2024 |
| Strike | 300 $ |
| Maturity | 20/12/2024 (157 Days) |
| Parity | 10 : 1 |
| Emission price | 0.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.51 € |
|---|---|
| Lowest since issue | 0.56 € |
| Spread | 0.14 € |
| Spread % | 9.66% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280
USD
Average target price
365.3
USD
Spread / Average Target
+30.50%
- Stock Market
- Certificates
- Certificat
